Display options
Cite
Tornes L, Delgado S, Garcia-Buitrago M, et al. Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis. Mult Scler Relat Disord. 2012;1(3):148-51doi: 10.1016/j.msard.2012.02.002.
Tornes, L., Delgado, S., Garcia-Buitrago, M., Ortega, M. R., & Rammohan, K. W. (2012). Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis. Multiple sclerosis and related disorders, 1(3), 148-51. https://doi.org/10.1016/j.msard.2012.02.002
Tornes, Leticia, et al. "Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis." Multiple sclerosis and related disorders vol. 1,3 (2012): 148-51. doi: https://doi.org/10.1016/j.msard.2012.02.002
Tornes L, Delgado S, Garcia-Buitrago M, Ortega MR, Rammohan KW. Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis. Mult Scler Relat Disord. 2012 Jul;1(3):148-51. doi: 10.1016/j.msard.2012.02.002. Epub 2012 Mar 14. PMID: 25877082.
Copy Download .nbib Format: NLM
Share it on

Mult Scler Relat Disord. 2012 Jul;1(3):148-51. doi: 10.1016/j.msard.2012.02.002. Epub 2012 Mar 14.

Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis.

Multiple sclerosis and related disorders

Leticia Tornes, Silvia Delgado, Monica Garcia-Buitrago, Melissa R Ortega, Kottil W Rammohan

Affiliations

  1. University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: [email protected].
  2. University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: [email protected].
  3. University of Miami Miller School of Medicine, Department of Pathology, 1611 NW 12 Ave Holtz Building, #2042, USA. Electronic address: [email protected].
  4. University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: [email protected].
  5. University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: [email protected].

PMID: 25877082 DOI: 10.1016/j.msard.2012.02.002

Abstract

Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.

Copyright © 2012 Elsevier B.V. All rights reserved.

Keywords: Adverse effects; Focal segmental glomerulosclerosis; Glomerulonephritis; Interferon beta; Kidney failure; Multiple sclerosis

Publication Types